Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Anti-CD117 mAb synergizes with 5-azacytidine to augment engraftment of HSCs in mice

Andriyana Bankova • 26 Feb 2021
TCT 2021
General

Andriyana K. Bankova, MD, Stanford University School of Medicine, Stanford, CA, explores the use of a CD117-targeting monoclonal antibody (mAb) in combination with azacytidine to augment engraftment of hematopoietic stem cells (HSCs) in a mice model. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Andriyana Bankova

Treating CRS and ICANS: current approaches and future outlooks
2:09
Treating CRS and ICANS: current approaches and future outlooks
Andriyana Bankova • 21 Feb 2023
Management strategies for early and late infections in patients undergoing CAR-T cell therapy
6:59
Management strategies for early and late infections in patients undergoing CAR-T cell therapy
Andriyana Bankova • 21 Feb 2023
Clinical outcomes of cryopreserved graft recipients following allo-HCT
4:58
Clinical outcomes of cryopreserved graft recipients following allo-HCT
Andriyana Bankova • 26 Feb 2021

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals